Skip to main content
European Stroke Journal logoLink to European Stroke Journal
. 2023 Jul 11;8(3):618–628. doi: 10.1177/23969873231186042

Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020

Diana Aguiar de Sousa 1, Arlene Wilkie 2, Bo Norrving 3, Chris Macey 4, Claudio Bassetti 5, Cristina Tiu 6, Greg Roth 7, Grethe Lunde 2, Hanne Christensen 8, Jens Fiehler 9, Francesca Romana Pezzella 10, Martin Dichgans 11, Melinda B Roaldsen 12, Peter Kelly 13, Robert Mikulik 14, Simona Sacco 15, Valeria Caso 16, Urs Fischer 17,
PMCID: PMC10472963  PMID: 37431768

Abstract

Introduction:

We assessed best available data on access and delivery of acute stroke unit (SU) care, intravenous thrombolysis (IVT) and endovascular treatment (EVT) in the European region in 2019 and 2020.

Patients and methods:

We compared national data per number of inhabitants and per 100 annual incident first-ever ischaemic strokes (AIIS) in 46 countries. Population estimates and ischaemic stroke incidence were based on United Nations data and the Global Burden of Disease Report 2019, respectively.

Results:

The estimated mean number of acute SUs in 2019 was 3.68 (95% CI: 2.90–4.45) per one million inhabitants (MIH) with 7/44 countries having less than one SU per one MIH. The estimated mean annual number of IVTs was 21.03 (95% CI: 15.63–26.43) per 100,000 and 17.14% (95% CI: 12.98–21.30) of the AIIS in 2019, with highest country rates at 79.19 and 52.66%, respectively, and 15 countries delivering less than 10 IVT per 100,000. The estimated mean annual number of EVTs in 2019 was 7.87 (95% CI: 5.96–9.77) per 100,000 and 6.91% (95% CI: 5.15–8.67) of AIIS, with 11 countries delivering less than 1.5 EVT per 100,000. Rates of SUs, IVT and EVT were stable in 2020. There was an increase in mean rates of SUs, IVT and EVT compared to similar data from 2016.

Conclusion:

Although there was an increase in reperfusion treatment rates in many countries between 2016 and 2019, this was halted in 2020. There are persistent major inequalities in acute stroke treatment in the European region. Tailored strategies directed to the most vulnerable regions should be prioritised.

Keywords: Europe, acute stroke treatment, health care resources, stroke unit, intravenous thrombolysis, endovascular treatment, stroke care implementation

Introduction

From 1990 to 2019, the absolute number of incident strokes increased by 70.0% and, in 2019, there were 12.2 million incident cases of stroke globally. 1 Stroke remains the second most common cause of death in Europe, where it is responsible for more than one million deaths per year and the leading cause of long-term disability. 2 Across European Union countries, stroke accounted for 375,000 deaths in 2017, and the number is expected to rise by one-third by 2035 due to population ageing and increases in some risk factors. 3 Among all strokes, the ischaemic subtype is the most common, representing approximately 80% of cases in Europe. 4 As a result, stroke is associated with a high use of health and social-care resources, with 8% of the 798 billion cost of brain disorders being attributable to stroke. 5 Productivity losses cost was estimated to be 12 billion euros in Europe alone, equally split between early death and lost working days. 6

The main pillars of acute ischaemic stroke treatment are stroke unit (SU) care7,8 and treatments promoting reperfusion, namely intravenous thrombolysis (IVT) 9 and endovascular treatment (EVT). 10 These three interventions are highly effective in reducing mortality and morbidity. Although information on the implementation of these treatment strategies is crucial to guide any tailored measures, a single study with unified methodology designed to provide complete information for all European countries is unlikely to be feasible. In 2016, a task force of European associations representing professionals dedicated to stroke and patient organisations collected data on the access to and delivery of SU care, IVT and EVT in 44 countries in the European region. 11 The results of this study confirmed large disparities across Europe. Ten countries did not have at least one SU per million inhabitants, 15 countries had thrombolysis rates below 5% and the overall proportion of patients with acute ischaemic stroke treated with mechanical thrombectomy was less than 2%. Since then, large efforts have been made in several European countries in order to increase the access to acute stroke treatment. Of note, ESO and SAFE have started a programme for the implementation of the Stroke Action plan for Europe12,13 and the ESO-EAST programme, dedicated to the improvement of stroke care in Eastern Europe countries also runs in parallel 14 Moreover, the time-window for IVT and EVT has been extended, increasing the number of potentially eligible patients. 9 In 2020, the coronavirus disease 2019 (COVID-19) pandemic placed an unprecedented burden on health systems, thus threatening their ability to operate effectively for acute conditions such as cerebrovascular disorders.15,16

To better allocate resources to deal with stroke burden in Europe, it is crucial to identify the evolution of these metrics of delivery of acute stroke care, track the persisting asymmetries, and correctly identify the most vulnerable areas. Therefore, the European Stroke Organisation (ESO) together with the European Academy of Neurology (EAN) and the European Society of Minimally Invasive Neurological Therapy (ESMINT) and the Stroke Alliance for Europe (SAFE) surveyed the access to and delivery rates of acute SU care, IVT and EVT throughout Europe in 2019 and 2020.

Objectives

We aimed to collect and compare national data on access to and delivery rates for acute SU care, IVT and EVT throughout the European region. We also aimed to estimate how many patients could be treated with IVT and EVT if the current highest treatment rates were to be followed in all countries.

Methods

Study design and participants

The current work was preceded by a survey to identify scientific societies related with stroke in all European countries, using the existing network of contacts provided by the European Stroke Organisation and the working group dedicated to the implementation of the Stroke Action Plan for Europe, created by ESO and SAFE in 2018. As a second step, this committee completed a survey directed to these national scientific societies on the best available national sources of information concerning surveillance data on stroke. Finally, the leadership of the identified national scientific societies was invited to nominate the national experts for the task of collecting the best available national data on the number of acute SU, IVT and EVT interventions delivered in 2019 and 2020 and the corresponding information on the data sources. These experts would be preferably those related with the public health surveillance and data collection in the field of stroke. Their names and affiliations are shown in Supplemental Appendix 1. A representative from a patient organisation (SAFE) was involved in all stages of the project to incorporate the patient perspective and ensure dissemination of the results to national stroke support organisations.

We adopted the World Health Organization (WHO)’s definition of the European region as including 53 countries. Countries with less than 100,000 inhabitants (Monaco, Andorra, Vatican City, Liechtenstein and San Marino) were excluded. The definition of SU was based on the national criteria in place, at each participating country. Because there is a prospective registry audited by the regional health authority in the Spanish region of Catalonia, we also collected data for this specific province.

Data collection

The study was drafted by the steering committee after a series of meetings and consisted of 14 items. A pilot study was performed in Denmark, Austria, Switzerland, Czechia and Sweden to assess feasibility. The study was performed between March, 2021 and July, 2022. Collected data were independently reviewed by two authors (UF, DAS). Whenever there was ambiguity and/or missing or conflicting responses, the steering committee requested clarifications.

Data analyses

Our analyses focused on access to and delivery rates of acute SU care, IVT and EVT as well as the number of centres delivering IVT and EVT. All data were analysed using appropriate descriptive methods. We calculated crude rates of acute SUs, centres providing IVT, and centres providing EVT per one million inhabitants, in each country, using United Nations population estimates (2019 Revision of World Population Prospects), 17 with the exception of Kosovo, for which official governmental information was used. Similar calculations were done for annual numbers of IVT and EVT performed per 100,000 inhabitants. The annual incidence of first-ever acute ischaemic stroke per country was based on the estimates from the Global Burden of Disease Report (2019)1,18 and was used to calculate the rate of IVT and EVT treatments per 100 first-ever acute ischaemic strokes and which is described as a percentage. Linear regression was used to determine the strength of the association between gross domestic product (GDP) per capita (PPP) and the annual number of IVT or EVT treatments for ischaemic stroke delivered per 100,000 inhabitants in each country.

Additionally, we calculated how many additional patients could be treated if an IVT rate of 40% could be achieved in all countries. Similar calculations were done for patients treated with EVT if an EVT rate of 16% could be achieved in all countries. Both cut-offs were determined using a data-driven approach, specifically based on the next lower whole-numbered value observed among the three countries with the highest rates. This approach ensured that the calculated thresholds for IVT and EVT were grounded in the existing data and represented achievable targets across all countries The data obtained from the study were collated and analysed in Microsoft Excel, version 16.62 (Microsoft Corporation, Redmond, WA, USA).

Results

Overall, 46/51 invited countries participated. The total number of inhabitants in these 46 participating countries was estimated to be 878.6 million according to the United National Population prospects. The total incidence of first-ever ischaemic stroke in these 46 countries was 1.195 million cases in 2019, according to the Global Burden of Disease estimates. Data was based on national stroke registries in 12 countries and one province (Catalonia, Supplemental Table 2) and on health surveillance data collected by governmental bodies in nine countries (Supplemental Table 1). Two countries (Czechia and Croatia) contribute extensively to international stroke registries and therefore the data obtained can be deemed as having appropriate national coverage, even in the absence of a dedicated national registry. For the remaining countries, data sources are described in Supplemental Table 1. They include restricted registries (e.g. a national registry for endovascular treatment in Italy), national surveys, or direct contact with national stroke units and hospitals dedicated to acute stroke care.

Acute stroke units, IVT hospitals and EVT centres

Information on acute SU care was provided for 44 countries. Overall, in 2019 there were 2165 acute SUs in 44 countries, corresponding to a pooled mean of 3.68 SUs per million inhabitants (95% CI: 2.90–4.45) in 2019. There was a considerable heterogeneity among the 44 countries. The country with highest rate had 11 acute SUs per one million population. Seven countries had less than one acute SU per one million inhabitants. Data for 2020 was mostly similar to that of 2019 (Table 2).

Table 2.

Overview of stroke treatment facilities and reperfusion treatments by country, 2020.

Population UN prospects* No. Of Stroke Units Rate of Stroke Units per million inhabitants IVT hospitals Rate of IVT hospitals per million inhabitants No. IVT for acute ischaemic stroke Rate of IVT treatments per 100,000 inhabitants Percentage of incident ischaemic strokes treated with IVT EVT hospitals Rate of EVT hospitals per million inhabitants No. EVT for acute ischaemic stroke Rate of EVT treatments per 100,000 inhabitants Percentage of incident ischaemic strokes treated with EVT
Albania 2,877,800 2 0.69 2 0.69 125 4.34 4.32 1 0.35 34 1.18 1.17
Armenia 296,3234 2 0.68 2 0.68 142 4.79 4.78 2 0.68 239 8.07 8.04
Austria 9,006,400 37 4.13 37 4.13 2710 30.09 31.17 10 1.12 884 9.82 10.17
Belgium 11,589,616 60 5.20 60 5.20 2120 18.29 20.90 18 1.56 1077 9.29 10.62
Bosnia and Herzegovina 3,280,815 10 3.03 10 3.03 52 1.58 0.55 2 0.61 2 0.06 0.02
Bulgaria 6,948,445 49 7.00 49 7.00 954 13.73 3.95 4 0.57 74 1.06 0.31
Croatia 4,105,268 23 5.57 23 5.57 650 15.83 7.74 5 1.21 502 12.23 5.98
Czechia 10,708,982 45 4.21 45 4.21 4632 43.25 27.29 15 1.40 1449 13.53 8.54
Cyprus 1,207,361 0 0.00 2 1.67 NA NA NA 1 0.83 NA NA NA
Denmark 5,792,203 15 2.60 11 1.91 2607 45.01 48.10 4 0.69 747 12.90 13.78
Germany 83,783,945 535 6.41 535 6.41 34,896 41.65 35.06 178 2.13 17,414 20.78 17.50
Estonia 1,326,539 6 4.53 6 4.53 1008 75.99 62.44 3 2.26 260 19.60 16.11
Finland 5,540,718 21 3.80 22 3.98 1050 18.95 15.50 5 0.90 700 12.63 10.33
France 65,273,512 140 2.15 208 3.19 NA NA NA 42 0.64 7189 11.01 12.95
Georgia 3,989,175 8 2.00 8 2.00 84 2.11 1.61 4 1.00 47 1.18 0.90
Greece 10,423,056 10 0.95 40 3.82 600 3.84 2.83 12 1.15 70 0.67 0.35
Hungary 9,660,350 39 4.03 39 4.03 3042 31.49 14.46 7 0.72 1274 13.19 6.06
Iceland 341,250 1 2.95 5 14.75 NA NA NA 1 2.95 NA NA NA
Ireland 4,937,796 25 5.12 25 5.12 466 9.44 17.95 25 5.12 379 7.68 14.60
Israel 8,656,000 26 3.00 26 3.00 719 8.31 13.80 9 1.04 442 5.11 8.48
Italy 60,461,828 223 3.68 223 3.68 10,821 17.90 17.72 66 1.09 5579 9.23 9.14
Kosovo 1,790,133 6 3.37 0 0.00 0 0.00 0.00 1 0.56 12 0.67 0.68
Kyrgyzstan 6,524,191 6 0.94 2 0.31 NA NA NA 2 0.31 NA NA NA
Latvia 1,886,202 8 4.20 8 4.20 1623 86.05 29.22 3 1.57 211 11.19 3.80
Lithuania 2,722,291 11 3.99 11 3.99 1206 44.30 16.10 6 2.17 606 22.26 8.09
Luxembourg 625,976 4 6.50 4 6.50 NA NA NA 4 6.50 28 4.47 7.32
Malta 441,539 1 2.27 1 2.27 NA NA NA 1 2.27 31 7.02 7.85
Montenegro 628,062 6 9.55 6 9.55 44 7.01 5.17 1 1.59 7 1.11 0.82
North Macedonia 2,083,380 4 1.92 4 1.92 25 1.20 0.46 1 0.48 3 0.14 0.06
Norway 5,421,242 46 8.55 46 8.55 1587 29.27 29.30 7 1.30 410 7.56 7.57
Poland 37,846,605 174 4.59 174 4.59 10,905 28.81 19.45 17 0.45 2144 5.66 3.82
Portugal 10,196,707 38 3.72 38 3.72 2112 20.71 16.82 10 0.98 2203 21.61 17.55
Republic of Moldova 4,033,963 5 1.24 8 1.98 55 1.36 0.89 2 0.49 5 0.12 0.08
Romania 19,237,682 40 2.07 40 2.07 2206 11.47 4.51 5 0.26 214 1.11 0.44
Serbia 8,737,370 25 2.85 20 2.28 500 5.72 2.08 5 0.57 100 1.14 0.42
Slovakia 5,459,643 43 7.88 43 7.88 2096 38.39 21.80 10 1.83 944 17.29 9.82
Slovenia 2,078,932 24 11.55 12 5.77 586 28.19 22.33 2 0.96 206 9.91 7.85
Spain 46,754,783 65 1.39 80 1.71 4860 10.39 11.57 48 1.03 5766 12.33 13.72
Sweden 10,099,270 72 7.17 72 7.17 2273 22.51 20.18 6 0.60 942 9.33 8.36
Switzerland 8,654,618 19 2.21 35 4.07 1475 17.04 22.50 10 1.16 1281 14.80 19.54
The Netherlands 17,134,873 NA NA 64 3.74 6490 37.88 39.12 18 1.05 2322 13.55 14.00
Turkey 84,339,000 84 1.01 148 1.77 NA NA NA 64 0.77 NA NA NA
Ukraine 43,733,759 14 0.32 97 2.20 1573 3.60 1.80 20 0.45 362 0.83 0.41
United Kingdom 67,886,004 NA NA NA NA 9351 13.77 18.94 NA NA 1603 2.36 3.25
Uzbekistan 33,469,199 0 0 NA NA 100 0.30 4.17 0 0 0 0.00 0.00

NA: not available; IVT: intravenous thrombolysis; EVT: endovascular treatment.

*

Except Kosovo (source: national estimates).

Overall, 44 countries reported the number of hospitals delivering IVT and EVT (Tables 1 and 2). In 2019, IVT was performed at 2468 hospitals, corresponding to a mean number of 4.04 (95% CI: 3.23–4.85) IVT hospitals per one million inhabitants. The three countries with highest rates had more than 8 IVT hospitals per one million population (Iceland, Montenegro and Norway). EVT was performed at 646 stroke centres, corresponding to a mean number of 1.03 (95% CI: 0.84–1.22) EVT centres per one million inhabitants. Five countries had more than two EVT centres per one million population (Germany, Lithuania, Estonia, Malta and Iceland). Twenty-six countries had less than one stroke centre capable of performing EVT per one million inhabitants. Data for 2020 is described in Table 2.

Table 1.

Overview of stroke treatment facilities and reperfusion treatments by country, 2019.

Population UN prospects* No. of first-ever incident ischaemic strokes per year No. Of Stroke Units Rate of Stroke Units per million inhabitants No. of beds dedicated to stroke care (Stroke units/centres) No. of beds dedicated to stroke care in units able to provide IVT No. of beds dedicated to stroke care in units able to provide EVT IVT hospitals Rate of IVT hospitals per million inhabitants No. IVT for acute ischaemic stroke Rate of IVT treatments per 100,000 inhabitants Percentage of incident ischaemic strokes treated with IVT EVT hospitals Rate of EVT hospitals per million inhabitants No. EVT for acute ischaemic stroke Rate of EVT treatments per 100,000 inhabitants Percentage of incident ischaemic strokes treated with EVT
Albania 2,881,000 2894 2 0.69 50 7 4 2 0.69 160 5.55 5.53 1 0.35 32 1.11 1.11
Armenia 2,957,728 2972 2 0.68 200 30 30 2 0.68 226 7.64 7.61 2 0.68 159 5.38 5.35
Austria 8,955,108 8695 37 4.13 194 194 60 37 4.13 2675 29.87 30.77 10 1.12 1001 11.18 11.51
Belgium 11,539,326 10,143 60 5.20 240 240 78 60 5.20 2120 18.37 20.90 18 1.56 1077 9.33 10.62
Bosnia and Herzegovina 3,300,998 9404 10 3.03 150 80 15 10 3.03 78 2.36 0.83 2 0.61 3 0.09 0.03
Bulgaria 7,000,117 24,139 48 6.86 NA NA NA 48 6.86 1119 15.99 4.64 4 0.57 79 1.13 0.33
Croatia 4,130,000 8396 23 5.57 300 125 60 23 5.57 800 19.37 9.53 4 0.97 434 10.51 5.17
Czechia 10,689,213 16,974 45 4.21 2035 2035 819 45 4.21 5241 49.03 30.88 15 1.40 1503 14.06 8.85
Cyprus 1,198,574 694 1 0.83 5 5 0 4 3.34 NA NA NA 2 1.67 NA NA NA
Denmark 5,771,877 5420 16 2.77 NA NA NA 11 1.91 2604 45.12 48.04 4 0.69 730 12.65 13.47
Germany 83,517,046 99,537 535 6.41 3210 3210 1424 535 6.41 37,009 44.31 37.18 178 2.13 16,833 20.16 16.91
Estonia 1,325,649 1614 6 4.53 144 144 82 6 4.53 850 64.12 52.66 3 2.26 190 14.33 11.77
Finland 5,532,159 6774 21 3.80 90 50 40 22 3.98 1200 21.69 17.71 5 0.90 740 13.38 10.92
France 65,129,731 55,516 140 2.15 NA 841 326 208 3.19 11,520 17.69 20.75 42 0.64 7570 11.62 13.64
Georgia 3,996,762 5225 5 1.25 NA NA NA 5 1.25 46 1.15 0.88 3 0.75 23 0.58 0.44
Greece 10,473,452 14,143 10 0.95 30 15 5 40 3.82 600 5.39 4.24 12 1.15 60 0.57 0.42
Hungary 9,684,680 21,030 39 4.03 NA NA NA 39 4.03 3195 32.99 15.19 7 0.72 1197 12.36 5.69
Iceland 339,037 250 1 2.95 12 12 12 5 14.75 NA NA NA 1 2.95 NA NA NA
Ireland 4,882,498 2595 25 5.12 210 160 36 25 5.12 389 7.97 14.99 2 0.41 302 6.19 11.64
Israel 8,656,000 5212 26 3.00 60 10 50 26 3.00 1500 17.61 28.78 9 1.04 749 8.79 14.37
Italy 60,550,092 61,057 223 3.68 737 737 NA 223 3.68 11,948 19.73 19.57 66 1.09 4808 7.94 7.87
Kosovo 1,788,878 1768 6 3.37 105 0 0 0 0.00 0 0.00 0.00 1 0.56 0 0.00 0.00
Kyrgyzstan 6,415,851 4426 5 0.78 186 20 10 1 0.16 NA NA NA 1 0.16 NA NA NA
Latvia 1,906,740 5553 8 4.20 250 50 24 8 4.20 1510 79.19 27.19 2 1.05 184 9.65 3.31
Lithuania 2,759,631 7491 11 3.99 120 120 92 11 3.99 1219 44.17 16.27 6 2.17 518 18.77 6.92
Luxembourg 615,730 383 4 6.50 17 17 6 4 6.50 73** 11.86 19.08 1 1.62 28 4.55 7.32
Malta 440,377 395 1 2.27 4 4 4 1 2.27 NA NA NA 1 2.27 38 8.63 9.62
Montenegro 627,988 851 6 9.55 115 115 25 6 9.55 50 7.96 5.88 1 1.59 11 1.75 1.29
North Macedonia 2,083,458 5425 4 1.92 NA NA NA 4 1.92 67 3.22 1.23 1 0.48 31 1.49 0.57
Norway 5,378,859 5416 46 8.55 435 435 118 46 8.55 1691 31.44 31.22 5 0.93 487 9.05 8.99
Poland 37,887,771 56,055 174 4.59 2700 2700 350 174 4.59 11,716 30.92 20.90 17 0.45 1132 2.99 2.02
Portugal 10,226,178 12,554 38 3.72 270 270 90 38 3.72 2467 24.12 19.65 10 0.98 2057 20.12 16.39
Republic of Moldova 4,043,258 6182 5 1.24 190 107 18 7 1.73 80 1.98 1.29 2 0.49 14 0.35 0.23
Romania 19,364,558 48,906 39 2.01 NA 800 100 39 2.01 2296 11.86 4.69 4 0.21 132 0.68 0.27
Russian Federation 145,872,260 321,938 NA NA NA NA NA NA NA 19,794 13.57 6.15 NA NA NA NA NA
Serbia 8,772,228 24,038 25 2.85 NA NA NA 20 2.28 800 9.12 3.33 5 0.57 160 1.82 0.67
Slovakia 5,457,012 9617 43 7.88 559 215 60 43 7.88 2030 37.20 21.11 10 1.83 983 18.01 10.22
Slovenia 2,078,654 2624 24 11.55 218 218 16 12 5.77 625 30.07 23.82 2 0.96 295 14.19 11.24
Spain 46,736,782 42,020 65 1.39 342 NA NA 80 1.71 5367 11.48 12.77 47 1.03 5911 12.65 14.07
Sweden 10,036,391 11,265 72 7.17 1023 1023 95 72 7.17 2571 25.62 22.82 6 0.60 927 9.24 8.23
Switzerland 8,591,361 6556 19 2.21 350 150 100 35 4.07 1287 14.98 19.63 10 1.16 1428 16.62 21.78
The Netherlands 17,097,123 16,590 NA NA NA NA NA 64 3.74 6797 39.76 40.97 17 0.99 2233 13.06 13.46
Turkey 83,430,000 81,599 84 1.01 1200 1200 650 148 1.77 8000 9.59 9.80 64 0.77 2300 2.76 2.82
Ukraine 43,993,643 87,590 6 0.14 140 60 140 74 1.68 912 2.07 1.04 17 0.39 197 0.45 0.22
United Kingdom 67,530,161 49,376 205 3.04 5377 NA NA 205 3.04 11,314 16.75 22.91 26 0.39 1467 2.17 2.97
Uzbekistan 32,981,715 23,984 0 0 0 0 0 NA NA 100 0.30 0.42 0 0 0 0.00 0.00

UN: United Nations; NA: not available; IVT: intravenous thrombolysis; EVT: endovascular treatment.

*

Except Kosovo (source: national estimates from the Statistical Office of Kosovo).

**

Data on number of intravenous thrombolysis for acute ischaemic stroke from three out of four national hospitals dedicated to acute stroke care.

Intravenous thrombolysis (IVT)

Data on the number of IVTs performed in 2019 was provided for 42 countries (Table 1). IVT was not available in Kosovo. The number of IVTs performed came from national registries in 13 countries. The remaining countries provided data collected from governmental sources or by direct contact of national stroke units (Supplemental Table 1).

Overall, the total annual number of patients receiving IVT in these 42 European countries was 164,011 in 2019. In 2019, the estimated mean number of IVTs per 100,000 inhabitants was 21.03 (95% CI: 15.63–26.43) and 17.14% (95% CI: 12.98–21.30) of the annual incident ischaemic strokes (Table 1), while the highest country rates were 79.19 and 52.66%, respectively (Figures 1 and 2). In 14 countries, the estimated annual numbers of IVT treatments delivered per 100,000 inhabitants were fewer than 10 whereas six countries had rates above 40 (Table 1 and Supplemental Figure 1).

Figure 1.

Figure 1.

Estimates for the annual rate of patients receiving intravenous thrombolysis per 100 000 inhabitants in 42 countries from the European region in 2019.

Figure 2.

Figure 2.

Estimates for the annual proportion of incident ischaemic strokes receiving intravenous thrombolysis in 42 countries from the European region in 2019.

Data on the number of IVTs performed in 2020 was provided for 38 countries (Table 2). In 2020, the estimated mean number of IVTs per 100,000 inhabitants was 20.96 (95% CI: 14.60–27.32) and 16.59% (95% CI: 12.062–21.16) of the annual incident ischaemic strokes (Table 1), while the highest country rates were 86.05 and 62.44%, respectively (Supplemental Figures 2 and 3).

There was a trend towards an association between GDP per capita and the annual number of IVT treatments for ischaemic stroke delivered per 100,000 inhabitants in each country (p = 0.068) (Supplemental Figure 4).

Endovascular treatment (EVT)

Forty-one countries provided information on annual numbers of EVTs performed in 2019 (Table 1). The number of EVTs performed came from national registries in 14 countries. The remaining countries provided data collected from governmental sources or by direct contact of national stroke units (Supplemental Table 1).

Overall, 58,023 procedures were performed in 2019 in these 42 countries, corresponding to a mean number of 7.87 (95% CI: 5.96–9.77) procedures per 100,000 inhabitants and 6.91% (95% CI: 5.15–8.67) of annual incident ischaemic strokes, while highest country rates were 20.16 and 21.78%, respectively. The annual number of treatments delivered was less than 1.5 per 100,000 inhabitants in 11 countries, whereas two countries reported EVT rates above 20 per 100,000 (Supplemental Figure 7). Likewise, while 11 countries had an estimated EVT treatment rate of less than 1% of annual ischaemic strokes, three countries had treatment rates of more than 16% (Figures 3 and 4).

Figure 3.

Figure 3.

Estimates for the annual rate of patients receiving endovascular treatment per 100,000 inhabitants in 42 countries from the European region in 2019.

Figure 4.

Figure 4.

Estimates for the annual proportion of incident ischaemic strokes receiving endovascular treatment in 42 countries from the European region in 2019.

Data on the number of EVTs performed in 2020 was provided for 41 countries (Table 2). In 2020, the estimated mean number of EVTs per 100,000 inhabitants was 8.14 (95% CI: 6.1.0–10.18) and 7.09% (95% CI: 5.31–8.87) of the annual incident ischaemic strokes, while the highest country rates were 22.26 and 19.54%, respectively (Supplemental Figures 5 and 6).

There was an association between GDP per capita and the annual number of endovascular treatments for ischaemic stroke delivered per 100,000 inhabitants in each country (p = 0.004) (Supplemental Figure 8).

Estimation of the number of potential additional reperfusion treatments using treatment rates in best performing countries as benchmark

In 2019, the practice rate for IVT was above 40% in three countries. The estimated number of additional patients who could be treated with IVT if this treatment rate could be also achieved in the other 39 countries in the European region for which data is available is 312,346 (Table 3).

Table 3.

Estimated number of additional intravenous thrombolysis and endovascular treatments per country, assuming achievement of 40% and 16% rates, respectively, in 2019.

No. of additional IVT per year (target rate 40%, 2019) No. of additional EVT per year (target rate 16%, 2019)
Albania 998 431
Armenia 963 316
Austria 803 390
Belgium 1937 546
Bosnia and Herzegovina 3683 1502
Bulgaria 8536 3783
Croatia 2559 909
Czechia 1549 1213
Denmark N/A 137
Estonia N/A 68
Finland 1510 344
France 10,687 1313
Georgia 2044 813
Germany 2806 N/A
Greece 5057 2203
Hungary 5217 2168
Ireland 649 113
Israel 585 85
Italy 12,475 4961
Kosovo 490 196
Latvia 711 705
Lithuania 1777 681
Luxembourg 80 33
Malta No data 25
Montenegro 290 125
Netherlands N/A 421
North Macedonia 2103 837
Norway 475 380
Poland 10,706 7837
Portugal 2554 N/A
Republic of Moldova 2393 975
Romania 17,267 7693
Russian Federation 108,981 No data
Serbia 8815 3686
Slovakia 1817 556
Slovenia 425 125
Spain 11,441 812
Sweden 1935 875
Switzerland 1335 N/A
Turkey 24,639 10,756
Ukraine 34,124 13,817
United Kingdom 8436 6433
Uzbekistan 9494 3837
Total 312,347 82,101

N/A: Not Applicable, indicating that the respective IVT or EVT benchmark has already been met or exceeded for that country.

IVT: intravenous thrombolysis; EVT: endovascular treatment.

Concerning EVT, the practice rate was above 16% in the three top countries. If we extrapolate this as an achievable proportion of eligible patients in the other participating countries in the European region, the estimated number of additional patients who could have been treated with EVT in 2019 was 82,101 (Table 3).

Discussion

The current results show persisting inequalities in the provision of acute stroke care among countries in the WHO European region, particularly concerning its three main components (stroke unit care, IVT and EVT). For many countries, especially those with lower income, the number of SUs and rates of IVT and EVT are far below what was achieved in other European countries. Of note, the rate of IVT in the 11-participating middle-income countries (World Bank definition; Albania, Armenia, Bosnia and Herzegovina, Georgia, Kosovo, Montenegro, North Macedonia, Moldova, Serbia, Turkey and Uzbekistan) was 4.42 per 100,000 inhabitants in 2019 (95% CI: 26.61–70.53), which is a much lower rate compared with the 26.91 (95% CI: 20.83–32.99) treatments per 100,000 inhabitants in the other 31 participating high-income countries. The difference in EVT rates in middle and high-income countries is even more evident. In these 11 middle income countries for which data is available, the rate of EVT in 2019 was 1.39 (95% CI: 0.49–2.29) per 100,000 inhabitants, while it was 10.16 (95% CI: 8.13–12.19) for the 31 participating high-income countries. Lack of data on delivery of IVT and EVT or reachable stroke experts was also much more common in these countries (Azerbaijan, Belarus, Kazakhstan, Russia, Tajikistan, Kyrgyz Republic).

The availability of SUs and EVT centres per country also varied significantly throughout Europe and 27 countries did not reach the benchmark of one comprehensive stroke centre per one million inhabitants. 19 GDP per capita was a significant predictor of endovascular treatment delivery rates per 100,000 inhabitants.

Evolution of reperfusion treatment rates between 2016 and 2019

The comparison of the current results with previously collected data from 2016 show an increase in treatment delivery in most European countries, both of intravenous thrombolysis and endovascular treatment. 16 The estimated mean rate of IVT delivery in 2016, for the 43 countries participating in that previous study, was 14.2 per 100,000 inhabitants, while in 2019 it was 21.0, in the 42 countries for which data was available. Of note, Albania and Georgia initiated the use of IVT and substantial growth in the absolute number of annual IVT treatments was recorded in several countries, especially in Bulgaria, Croatia, Poland, Latvia, Luxembourg, Romania, Serbia, Slovakia, Turkey, and Ukraine.

An even sharper increase in the number of treated patients was seen for EVT, with a mean rate of treatment per 100,000 inhabitants raising from 3.7 to 7.9 in the same period. Nevertheless, seven of 42 participating countries still had a rate of IVT below five patients treated per 100,000 inhabitants, showing there was no major improvement in this regard, comparing with the 10 out of 43 countries with such low rates in 2016. Concerning EVT, it is also worth noting that while only three countries had a rate of EVT above 10 patients treated per 100,000 inhabitants in the 2016 study, there were 16 countries above this rate in 2019, and 14 in 2020. Remarkably, a more dedicated implementation was started in countries like Albania, Georgia, Macedonia, Luxembourg, Montenegro, Romania, and Serbia, albeit the treatment rates still remain low. Moreover, the absolute number of treatments more than doubled in 18 other countries during this period.

Another denominator used to compare national treatment rates in this analysis was the annual number of first-ever incident ischaemic strokes, based on the 2019 Global Burden of Disease Report. 1 Highest practice rate for IVT in 2019 was 53% (Estonia), whereas six countries had IVT rates of 30% or more. Highest EVT rate was 22% (Switzerland), with 15 countries achieving 10% or more. The comparison with the rates of incidence ischaemic strokes receiving reperfusion treatments that were estimated for 2016 is hampered by the sharp changes in the Global Burden of Disease estimates for this indicator. Of note, the estimated number of incident first-ever ischaemic strokes in 2019 is lower for most countries in region Europe comparing with the estimates that were available in 2016, which translates into higher treatment rates, even for countries with a similar absolute annual number of treatments. Besides, because data is lacking on recurrent ischaemic stroke, these rates should be an overestimation of the true proportion of acute ischaemic stroke patients receiving these interventions.

Evolution of reperfusion treatment rates between 2019 and 2020

Regarding the use of reperfusion treatments, the mean rate of delivery of IVT in the 42 assessed countries was around 17% of annual incident ischaemic strokes in 2019 and 2020. The mean number of IVTs also remained stable at 21.0 per 100,000 inhabitants in this 2-years period. The mean rate of delivery of EVT was around 7% of annual incident ischaemic strokes both in 2019 and 2020, with a mean rate of treatments per 100,000 inhabitants of 7.9 and 8.1 in 2019 and 2020, respectively.

There are no major differences in treatment rates between 2019 and 2020 for most countries. Although this may have been related with the challenges imposed by the COVID-19 pandemic during 2020, it should be closely monitored. The evident lack of proper implementation of EVT in several countries and the expansion of treatment indications should translate into an increase in treatment rates in the years to follow.

Benchmarking using countries with highest treatment rates

The current evidence of persistent large disparities strongly suggests that many potentially eligible patients are left untreated in several European countries. The estimates taking the best performing countries as benchmark suggest that more than 312,000 additional patients could have been treated with IVT and that more than 82,000 additional patients could have received EVT, only in 2019 and considering those countries for which data is available. However, these are still rather conservative estimates, since it is likely that the IVT and EVT rates in countries with the highest rates can also be improved, at least by reducing the time from symptom onset to patient admission.

Implications

This study is a comparison of the best available data on country rates of SUs, IVT and EVT in the European region. The finding that several countries are highly likely to be underperforming in some of these crucial metrics for the treatment of acute stroke should guide the future organisation of acute stroke care in these countries, the implementation of specific educational interventions directed to professionals, and stroke campaigns aimed at the general population. Moreover, the specific actions implemented by the European Scientific Societies and Patient Organisations should also consider this information in order to inform priorities of action, both at the educational level and in interventions directed at stakeholders and politicians. The implementation committee for the Stroke Action Plan for Europe is currently developing a platform called ‘Stroke Service Tracker’, which should facilitate a closer monitoring of these metrics, and stimulate national authorities to improve data collection on the delivery of stroke care, in collaboration with national stroke experts.

Strengths and limitations

A major strength of this study is the large number of participating countries. Secondly, the collected data was mostly based on official information collected at national level, either using national registers or other tools to collect health surveillance data, as diagnostic and treatment codes. Third, the data and the information on the respective source was provided by national experts in the field, who are aware and have access to the best available information in their country, including that written in national language. Importantly, both the nominated collaborators and the main data sources were identified using a two-step approach that started with a comprehensive survey of national experts to identify all relevant scientific societies in each country and corresponding contacts and was followed by a survey of stroke registries and other data sources, which was directed to nominated national experts involved in the collection of quality data related with stroke, also indicated by the national stroke societies.

However, there are several limitations: (1) There are differences in the methodology for data collection across the participating countries. In order to minimise this, we provide information on the specific data sources used in each country, as detailed by the national experts. (2) Some countries lack high quality data and thus the best of source of data was the local collection of absolute number of annual treatments by direct contact with national hospitals. Although the national experts are familiar with the local networks and, therefore, well aware of the national completeness of the data in terms of national coverage, the use of this methodology reduces the confidence in the exact estimates. (3) Given the lack of a uniform definition of SUs, some differences in SU rates are likely to be related to differences in national definitions. Moreover, the number of available beds and length of stay varies widely across SU, as well as the regional distribution of SU across each individual country. However, since data on the proportion of stroke patients that are first admitted to a SU is not available in many countries, this was considered to be a reasonable metric. (4) We have extracted the data on the annual number of first-ever incident ischaemic strokes from the 2019 Global Burden of Disease Report. Although this the most accepted global data on stroke incidence, the nationally obtained data for stroke incidence, usually based on analysis of diagnostic codes, may differ. Moreover, these estimates are for first-ever ischaemic stroke and recurrent strokes should be also treated stroke units and considered for reperfusion therapies. Data on the proportion of all strokes that are recurrent are sparse and differ between countries and with time. Nevertheless, even for countries with high quality stroke care and secondary prevention, such as Sweden, the estimated proportion of recurrent stroke between 2017 and 2019 was 21% of all strokes. 20 Therefore, data on the proportion of incident ischaemic strokes receiving treatment is overestimated and we have used the data of treatment delivery per 100,000 inhabitants as the main measure for comparisons across time. (5) Finally, this analysis is only focused on the absolute rate of delivery of three acute stroke treatment interventions, and it does not consider any other measures of quality performance, such as criteria for patient selection, time metrics for delivery of reperfusion treatments, functional outcome or any other patient-centred outcomes.

Conclusions

Despite the improvement in treatment rates in recent years, there are still major inequalities in treatment of acute stroke patients between countries in the European region. In many countries, rates for access to acute SU care, IVT, and EVT are far below highest country rates suggesting that potentially eligible patients have been left untreated. Together with the Stroke Action Plan for Europe, this data should support governments, health care providers, and scientific societies when developing national stroke plans to improve the reach and efficiency of acute stroke care and reinforce tailored educational interventions directed to professionals and general population, with the final goal to reduce stroke related mortality and morbidity in Europe.

Supplemental Material

sj-docx-1-eso-10.1177_23969873231186042 – Supplemental material for Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020

Supplemental material, sj-docx-1-eso-10.1177_23969873231186042 for Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020 by Diana Aguiar de Sousa, Arlene Wilkie, Bo Norrving, Chris Macey, Claudio Bassetti, Cristina Tiu, Greg Roth, Grethe Lunde, Hanne Christensen, Jens Fiehler, Francesca Romana Pezzella, Martin Dichgans, Melinda B Roaldsen, Peter Kelly, Robert Mikulik, Simona Sacco, Valeria Caso and Urs Fischer in European Stroke Journal

Footnotes

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent: The corresponding author (UF) affirms that this is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. All authors had access to the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Ethical approval: Not required

Guarantor: DAS and UF

Contributorship: UF and DAS initiated and coordinated the study. All authors contributed to the development of the survey. DAS performed the principal analysis and drafted the manuscript. All authors interpreted the data and revised critically the manuscript for important intellectual content.

Supplemental material: Supplemental material for this article is available online.

References

  • 1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021; 20: 795–820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. European Heart Network. European cardiovascular disease statistics. Brussels: European Heart Network, 2017. [Google Scholar]
  • 3. OECD/The King’s Fund. Is cardiovascular disease slowing improvements in life expectancy? OEDC and the kind’s fund workshop proceedings. Paris: OECD Publishing, 2020. [Google Scholar]
  • 4. Béjot Y, Bailly H, Durier J, et al. Epidemiology of stroke in Europe and trends for the 21st century. Presse Med 2016; 45: e391–e398. [DOI] [PubMed] [Google Scholar]
  • 5. Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19: 155–162. [DOI] [PubMed] [Google Scholar]
  • 6. Luengo-Fernandez R, Violato M, Candio P, et al. Economic burden of stroke across Europe: A population-based cost analysis. Eur Stroke J 2020; 5: 17–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Jørgensen HS, Nakayama H, Raaschou HO, et al. The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost. Stroke 1995; 26: 1178–1182. [DOI] [PubMed] [Google Scholar]
  • 8. Indredavik B, Bakke F, Slørdahl SA, et al. Stroke unit treatment. 10-year follow-up. Stroke 1999; 30: 1524–1527. [DOI] [PubMed] [Google Scholar]
  • 9. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. J Lancet 2014; 384: 1929–1935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO) – European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in Acute Ischaemic Stroke Endorsed by Stroke Alliance for Europe (SAFE). Eur Stroke J 2019; 4: 6–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Aguiar de Sousa D, von Martial R, Abilleira S, et al. Access to and delivery of acute ischaemic stroke treatments: A survey of national scientific societies and stroke experts in 44 European countries. Eur Stroke J 2019; 4: 13–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Norrving B, Barrick J, Davalos A, et al. Action plan for stroke in Europe 2018-2030. Eur Stroke J 2018; 3: 309–336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. European Stroke Organisation. Stroke Action Plan for Europe. Stroke Action Plan. https://eso-stroke.org/projects/stroke-action-plan/ (n.d., accessed 2 January 2023).
  • 14. Mikulík R, Caso V, Bornstein NM, et al. Enhancing and accelerating stroke treatment in Eastern European region: Methods and achievement of the ESO EAST program. Eur Stroke J 2020; 5: 204–212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Christensen H, Pezzella FR. Implementation of the Stroke Action Plan for Europe 2018–2030 during coronavirus disease-2019. Curr Opin Neurol 2021; 34: 55–60. [DOI] [PubMed] [Google Scholar]
  • 16. Aguiar de Sousa D, van der Worp HB, Caso V, et al. Maintaining stroke care in Europe during the COVID-19 pandemic: Results from an international survey of stroke professionals and practice recommendations from the European Stroke Organisation. Eur Stroke J 2020; 5: 230–236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2019: Data Booket. ST/ESA/SER. A/424, 2019.
  • 18. Institute for Health Metrics and Evaluation. VizHub - GDB compare. https://vizhub.healthdata.org/gbd-compare/ (n.d., accessed 18 April 2022).
  • 19. Grotta JC, Hacke W. Stroke neurologist’s perspective on the new endovascular trials. Stroke 2015; 46: 1447–1452. [DOI] [PubMed] [Google Scholar]
  • 20. Drescher C, Buchwald F, Ullberg T, et al. Epidemiology of first and recurrent ischemic stroke in Sweden 2010-2019: A Riksstroke Study. Neuroepidemiology 2022; 56: 433–442. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

sj-docx-1-eso-10.1177_23969873231186042 – Supplemental material for Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020

Supplemental material, sj-docx-1-eso-10.1177_23969873231186042 for Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020 by Diana Aguiar de Sousa, Arlene Wilkie, Bo Norrving, Chris Macey, Claudio Bassetti, Cristina Tiu, Greg Roth, Grethe Lunde, Hanne Christensen, Jens Fiehler, Francesca Romana Pezzella, Martin Dichgans, Melinda B Roaldsen, Peter Kelly, Robert Mikulik, Simona Sacco, Valeria Caso and Urs Fischer in European Stroke Journal


Articles from European Stroke Journal are provided here courtesy of SAGE Publications

RESOURCES